Perioperative changes of microbiome and metabolism in cardiac surgery patients

Perioperative changes of microbiome and metabolism in cardiac surgery patients - MetaHeart

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016493

Enrollment

100

Registered

2019-03-15

Start date

2019-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I25.1 R65.2 F05.8 T81.1 R57.2 J95.1 K56.7 R65.1

Interventions

Group 1: The study visits take place at fixed times (visit I - V) until discharge from hospital or death, if this event occurs before discharge. The visits take place at the following times: visit I o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Scheduled surgery using the use of cardio-pulmonary Bypass; male and female patients (age> 18 years); written informed consent of the patient.

Exclusion criteria

Exclusion criteria: Patients receiving antibiotic therapy; anal Stenosis; Perianal Bleeding or infections; Emergency indication for surgery; Endocarditis; Immunosuppression or therapy with glucocorticoids above the Cushing threshold (> 7.5 mg prednisolone equivalent); Existing chronic inflammatory bowel disease; Non-consenting Patient; Child Pugh Class C; Women during pregnancy and lactation; Participation in a clinical trial (intervention study) within the last 30 days; Current participation in another clinical trial (intervention study); Participation of the patient in this study earlier; Therapy restriction or setting (e.g., DNR order)

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the microbiome analysis is the quantitative change in the diversity of the four dominant bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria between baseline and the other investigation times. An exploratory analysis will identify microorganisms that may be drivers, protectors or biomarkers of metabolic disorders associated with poor postoperative outcome or altered metabolic processes.	—

Measure

Time frame

The primary endpoint of the microbiome analysis is the quantitative change in the diversity of the four dominant bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria between baseline and the other investigation times. An exploratory analysis will identify microorganisms that may be drivers, protectors or biomarkers of metabolic disorders associated with poor postoperative outcome or altered metabolic processes.

—

Secondary

Measure	Time frame
Secondary endpoints include the determination of typical metabolic metabolites from patients' blood samples using mass spectrometry-based technologies and the correlation of metabolite concentration changes with clinical outcome parameters.	—

Countries

Germany

Contacts

Public ContactMatthias Kott

Klinik für Anästhesiologie und Operative Intensivmedizin; Universitätsklinikum Schleswig-Holstein Campus Kiel

matthias.kott@uksh.de0431 500 20701

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026